Clinical trials: Adult Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Advanced Image Guidance Utilized in Liver Surgery
Advanced Image Guidance for this study was used during laparoscopic microwave ablation surgery to help the surgeon accurately place the ablation needle into the tumor of patients diagnosed with liver cancer.
- Trial name
- NCT01666145
- Testing
- Advanced Image Guidance
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Hepatocellular Carcinoma, Hepatoma
TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma
This is a single-center, prospective RCT to study the effectiveness of TACE and MWA combination therapy with MWA monotherapy for the treatment of early HCC. Primary outcome is 2-year intrahepatic disease-free survival.
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma
- Trial name
- NCT02704130
- Testing
- Transarterial embolization, Microwave Ablation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
This randomized phase III trial studies sorafenib tosylate and doxorubicin hydrochloride to see how well they work compared with sorafenib tosylate alone in treating patients with liver cancer that has spread to nearby tissue or…
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT01015833
- Testing
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- 673 sites in United States, Canada and 1 more
- Volunteers
- 356 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer
Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping anticancer drugs near the tumor.
- Trial name
- SATURNE (NCT01164202)
- Testing
- sunitinib malate, transarterial chemoembolization
- Where
- 31 sites in France
- Volunteers
- 78 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Bladder Cancer, Cervical Cancer
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00666978
- Testing
- smoking cessation intervention, bupropion hydrochloride, gene expression analysis
- Where
- 2 sites in United States
- Volunteers
- 540 people
- Sponsor
- Lisa Sanderson Cox, PhD
Advanced Hepatocellular Carcinoma, HCC
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
This is a Phase 2 Study of PD-0332991 in the treatment of patients with Advanced Hepatocellular Carcinoma (HCC), a type of adenocarcinoma and the most common type of liver tumor.
- Conditions
- Advanced Hepatocellular Carcinoma, HCC, Liver Cancer
- Trial name
- NCT01356628
- Testing
- PD-0332991
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with advanced or metastatic cholangiocarcinoma that cannot be removed by surgery.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder
- Trial name
- NCT01766219
- Testing
- 6,8-bis(benzylthio)octanoic acid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Colon Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer.
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT02293954
- Testing
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This phase II trial studies how well sorafenib tosylate and yttrium Y 90 glass microspheres work in treating patients with liver cancer that cannot be removed by surgery.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Recurrent Adult Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT01900002
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Cancer
Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, cisplatin, and mitomycin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing.
- Trial name
- NCT00049322
- Testing
- bevacizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT01730937
- Testing
- Sorafenib, stereotactic body radiation therapy
- Where
- 51 sites in United States, Australia and 3 more
- Volunteers
- 193 people
- Sponsor
- Radiation Therapy Oncology Group
Advanced Adult Hepatocellular Carcinoma
Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and tolerability of dalantercept plus sorafenib in patients with advanced hepatocellular carcinoma (HCC) to determine the recommended dose level of dalantercept in combination…
- Trial name
- NCT02024087
- Testing
- Dalantercept plus sorafenib
- Where
- 7 sites in United States
- Volunteers
- 21 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Advanced Adult Hepatocellular Carcinoma, Non-Resectable Hepatocellular Carcinoma
Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
This phase I/II trial studies the side effects and best dose of tivozanib and to see how well it works in treating patients with liver cancer that has spread to other parts of the body or cannot be removed by surgery.
- Trial name
- NCT01835223
- Testing
- Tivozanib (1mg), Tivozanib (1.5mg)
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Roswell Park Cancer Institute
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
This phase II trial studies how well giving sunitinib malate together with capecitabine works in treating patients with unresectable or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00787787
- Testing
- sunitinib malate, capecitabine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Washington
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
The purpose of the study is to determine whether once-daily dosing with ENMD-2076 will be a safe and effective treatment in patients with FLC.
- Trial name
- NCT02234986
- Testing
- ENMD-2076
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- CASI pharmaceuticals, Inc.
Advanced Hepatocellular Carcinoma With c-MET Dysregulation
Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.
This study is to find out if INC280 is safe and has beneficial effects in patients with advanced hepatocellular carcinoma known to have dysregulation of c-MET pathway.
- Trial name
- NCT01737827
- Testing
- INC280
- Where
- 8 sites in China, Hong Kong and 2 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma (HCC), Solid Malignancies
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401 as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and as single agent in patients with other solid…
- Trial name
- NCT02325739
- Testing
- FGF401, PDR001
- Where
- 27 sites in United States, China and 9 more
- Volunteers
- 172 people
- Sponsor
- Novartis Pharmaceuticals
Liver Cancer
Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NRR (NCT00483405)
- Testing
- cetuximab, capecitabine, oxaliplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center